about

Molecular diagnostics is an important element in realization of precision and personalized medicine, probably the single most important one. The Dx-Rx Institute is committed to working with companion diagnostics and drug-diagnostic codevelopment and has been involved in a number of collaborations both including academic and commercial partners. Throughout the years, the Dx-Rx Institute has published a number of articles on molecular diagnostics, companion diagnostics and drug-diagnostic co-development and has taken part in different educational activities at several European universities. The Dx-Rx Institute was established in 2009 by Dr. Jan Trøst Jørgensen as an independent institution where research goes hand in hand with consultancy.

Please visit the company profile at Linked
Frontiers Journal Dr. Jan Trøst Jørgensen, Dx-Rx Institute has acted as editor and coauthor on a book about companion and complementary diagnostics recently published by Academic Press. For more information on this book please visit the publisher’s website .

news

Dx-Rx Institute celebrate the 20th anniversary of Personalized Medicine
Read the April edition of the Biopeople Newsletter.
New book on Companion and Complementary Diagnostics
A new book on companion and complementary diagnostics edited by Dr. Jan Trøst Jørgensen will be published by Academic Press in May this year. The book gives an in-depth insight into the individual steps from the early biomarker discovery phase straight through to final regulatory approval as well as the clinical implementation.
Diagnostics and Precision Medicine
The Faculty of Science and Health, Dublin City University will soon offer a new postgraduate master program in Diagnostics and Precision Medicine. The program will focus on how diagnostics and therapeutics are revolutionizing healthcare and medicine by individualizing patient care. Dr. Jan Trøst Jørgensen, Dx-Rx Institute has been appointed as accreditation board member for this new important master program.
Companion Diagnostics and Oncology Drug Development
At the 10th Annual Meeting of the Danish Society for Pharmacology, January 17, 2018, a poster on Companion Diagnostics and Oncology Drug Development was presented. A copy of the abstract and the poster can be requested on: info@dx-rx.dk
Medical Herald
HER2 gene signal distribution patterns in gastroesophageal cancer described by Danish scientists
More than 125.000 have viewed this research topic!
More than 125.000 have viewed the research topic on Drug-Diagnostics Co-Development in Oncology published in Frontiers in Oncology
ASCO 2017
An abstract by JT Jørgensen, KB Nielsen, G Kjærsgaard et al. entitled 'HER2 amplification and gene signal distribution in gastroesophageal cancer', has been published in Journal of Clinical Oncology.
Biomarkers as an emerging growth area in Denmark
Dr. Jan Trøst Jørgensen has been appointed advisor to 'Biomarker as an emerging growth area' project.
Editorial Board Member
The Director of the Dx-Rx Institute, Dr. Jan Trøst Jørgensen, has been appointed member of the Editorial Board for World Journal of Gastrointestinal Oncology.
Critical Path to TB Drug Regimens
Based on an invitation from Bill & Melinda Gates Foundation, Dr. Jan Trøst Jørgensen will on March 22, 2017 give a keynote lecture on drug-diagnostic codevelopment at the Critical Path to TB Drug Regimens Workshop in Washington DC.
Annals of Translational Medicine
Dr. Jan Trøst Jørgensen, Dx-Rx Institute has been appointed member of the Editorial Board of Annals of Translational Medicine.
Workshop on Companion Diagnostics
On January 31, 2017, Dr. Jan Trøst Jørgensen will give a lecture entitled; 'Companion and Complementary Diagnostics: Clinical and Regulatory Perspectives'. Please visit webpage of BIO PEOPLE for further details
4th Joint EFLM-UEMS Congress - 'Laboratory medicine at the clinical interface'
At the 4th Joint EFLM-UEMS Congress, Warsaw, September 21-24th 2016, Dr. Jan Trøst Jørgensen will give a plenary lecture on the clinical application of companion diagnostics.
Most read article in Expert Review of Molecular Diagnostics
The article 'Companion diagnostic assays for PD-1/PD-L1 checkpoint inhibitors in NSCLC' is currently the most read article in Expert Review of Molecular Diagnostics. The article can be downloaded for free from the journals website.
Editorial Board Member
The Director of the Dx-Rx Institute, Dr. Jan Trøst Jørgensen, has been appointed member of the Editorial Board for Expert Review of Molecular Diagnostics.
Most read article in Expert Review of Molecular Diagnostics.
The article 'Companion diagnostics: the key to personalized medicine' is currently the most read article in 'Expert Review of Molecular Diagnostics'. The article can be downloaded for free from the journals website.
Companion Diagnostics for Cancer - Will NGS Play a Role?
The rapid accumulation of new knowledge on tumor biology resulting from next-gen sequencing is forcing stakeholders to continually rethink companion diagnostics. Read the article by Patricia Fitzpatrick Dimond published in GEN with contributions from Elizabeth Mansfield and Patricia Keegen, US FDA; Mya Thomae, Illumina and Jan Trøst Jørgensen, Dx-Rx Institute.
Finding the Right Patient for Your Drug
Interview with Jan Trøst Jørgensen (Elsevier Life Science Solutions News)
No Drug Designed For Me
Whitepaper on precision medicines and drug development from Elsevier R&D Solutions, Pharma & Life Sciences. Interview with Interviews with Dr. Jean Cui, Dr. Herbert Köppen, Dr. Scott Lusher, and Dr. Jan Trøst Jørgensen.
A comprehensive update on companion diagnostics
A special focus issue of Expert Review of Molecular Diagnostics.

selected publications from the dx-rx institute

A paradigm shift in biomarker guided oncology drug development
Ann Transl Med. 2019; 7 (7): 148
Clinical and Regulatory Aspects of Companion Diagnostic Development in Oncology
Clin Pharmacol Ther. 2018; 103(6): 999-1008
Companion and complementary diagnostics for first-line immune checkpoint inhibitor treatment in non-small cell lung cancer
Transl Lung Cancer Res. 2018; 7: S95-S99
When biomarkers define a drug indication
Expert Rev Mol Diagn. 2018; 18: 315-317
The ESMO Precision Medicine Glossary
Ann Oncol. 2018; 29(3): 781-782.
Companion and Complementary Diagnostics-Focus on PD-L1 Expression Assays for PD-1/PD-L1 Checkpoint Inhibitors in Non-Small Cell Lung Cancer
Ther Drug Monit. 2018; 40(1): 9-16.
Detection of MET amplification in gastroesophageal tumor specimens using IQFISH.
Ann Transl Med. 2017; 5(23): 458.
Gene Signal Distribution and HER2 Amplification in Gastroesophageal Cancer
J Cancer 2017; 8(9): 1517-1524
Companion diagnostics - a tool to improve pharmacotherapy
Ann Transl Med 2016; 4 (24): 482
Companion and Complementary Diagnostics: Clinical and Regulatory Perspectives.
Trends Cancer 2016; 2: 706-712.
Companion Diagnostics: From Biomarkers to Diagnostics
Reference Module in Chemistry, Molecular Sciences and Chemical Engineering (Elsevier, 2016).
The importance of predictive biomarkers in oncology drug development
Expert Rev Mol Diagn 2016; 16: 807-809
Companion diagnostic assays for PD-1/PD-L1 checkpoint inhibitors in NSCLC
Expert Rev Mol Diagn. 2016; 16: 131-133
Clinical application of companion diagnostics.
Trends Mol Med 2015; 21: 405-407.
Companion diagnostics: the key to personalized medicine.
Expert Rev Mol Diagn 2015; 15: 153-156.
Drug-diagnostics co-development in oncology
Front Oncol 2014; 4: 208.
Companion diagnostics for targeted cancer drugs
Clinical and regulatory aspects. Front Oncol 2014; 4: 105
The Role of HER2 in Gastric Cancer
Biological and Pharmacological aspects. World J Gastroenterol 2014; 20: 4526-35
A changing landscape for companion diagnostics
Expect Rev Mol Diagn 2013; 13: 667-669.
Companion Diagnostics in Oncology - current Status and Future Aspects
Oncology 2013; 85:59-68.
HER2 as a Prognostic Marker in Gastric Cancer - a Systematic Analysis of Data from the Literature
J Cancer 2012; 3: 137-144
A challenging drug development process in the era of personalized medicine
Drug Discov Today 2011; 16: 891-897.
Targeted HER2 Treatment in Advanced Gastric Cancer.
Oncology 2010; 78: 26-33.

the dx-rx institute has acted as editor on several other special issues and books: